Redeye raises its forecasts and Base Case slightly following a better-than-expected Q3 report. Organic EBITA* declined y/y, but that should not come as a surprise to anyone, and the unchanged margin guidance suggests a solid Q4.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/